Hu et al. reported the sequential use of CD7 CAR T-cell therapy and haploidentical allo-HSCT without myeloablation or pharmacologic GVHD prophylaxis in CD7-positive leukemias or lymphomas (seven out of the ten treated patients had AML). Here, CD7 is linked to lymphoma.